59th American Society of Hematology (ASH) Annual Meeting and Exposition

Abstracts regarding the Company's allogeneic, off-the-shelf, CAR T product candidates have been accepted for presentation at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting will be held from December 9 to 12, 2017 in Atlanta, GA.

Oral presentations:

• UCARTCS1 product candidate targeting Multiple Myeloma

502. Universal SLAMF7-Specific CAR T-Cells As Treatment for Multiple Myeloma

Abstract: https://ash.confex.com/ash/2017/webprogram/Paper106073.html

Session Name: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Novel Immunotherapeutic Strategies in Multiple Myeloma Session

Sunday, December 10, 2017 at 5:15 PM

Location: Bldg B, Lvl 3, B308-B309 (Georgia World Congress Center)

Rohit Mathur¹, Zheng Zhang¹, Jin He¹, Roman Galetto², Agnès Gouble², Isabelle Chion-Sotinel², Stéphanie Filipe², Annabelle Gariboldi², Tanooha Veeramachaneni¹, Elisabet E. Manasanch¹, Sheeba K. Thomas¹, Hans C. Lee¹, Krina K. Patel¹, Donna M. Weber¹, R. Eric Davis¹, Robert Z. Orlowski¹, Julianne Smith³, Jing Yang¹, and Sattva S. Neelapu¹

¹Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA

²Cellectis SA, 8 rue de la croix Jarry, 75013 Paris, France

³Cellectis Inc, 430 East 29th Street, 10016 New York, NY, USA

• UCART22 product candidate targeting B-Acute Lymphoblastic Leukemia

808. Pre-clinical Activity of Allogeneic Anti-CD22 CAR T-Cells for the Treatment of B-cell Acute Lymphoblastic Leukemia

Abstract: https://ash.confex.com/ash/2017/webprogram/Paper105595.html

Session Name: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: CAR-T Cell Immunotherapy

Monday, December 11, 2017: 5:15 PM

Location: Bldg C, Lvl 1, Hall C4 (Georgia World Congress Center)

Julia Wells PhD¹, Tianyu Cai, PhD¹, Cécile Schiffer-Manniou PhD², Stéphanie Filipe, PhD², Agnès Gouble, PhD², Roman Galetto, PhD², Nitin Jain MD¹, Elias Jabbour MD¹, Julianne SmithPhD³ and Marina Konopleva, MD, PhD¹

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

²Cellectis SA, Paris, France

³Cellectis Inc, New York, NY

Poster Presentation:

• UCART123 product candidate targeting Blastic Plasmacytoid Dendritic Cell Neoplasm

2625. Pre-Clinical Studies of Allogeneic Anti-CD123 CAR T-Cells for the Therapy of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Abstract: https://ash.confex.com/ash/2017/webprogram/Paper105789.html

Session Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II

Sunday, December 10, 2017 from 6:00 PM to 8:00 PM

Location: Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Tianyu Cai¹, Roman Galetto², Agnès Gouble², Julianne Smith³, Antonio Cavazos¹, Lina Han¹, Qi Zhang¹, Vinitha Kuruvilla¹, Sergej Konoplev⁴, Sattva S. Neelapu⁵, Andrew A. Lane⁶, Monica Guzman⁷, Hagop Kantarjian¹, Naveen Pemmaraju¹, Marina Konopleva¹

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

²Cellectis SA, Paris, France

³Cellectis Inc, New York, NY

⁴Department of Hematopathology, The University of MD Anderson Cancer Center, Houston, TX

⁵Department of Lymphoma and Myeloma, The University of MD Anderson Cancer Center, Houston, TX

⁶Dana-Farber Cancer Institute, Boston

⁷Department of Medicine, Weill Cornell Medical College, New York, NY